WATERTOWN, Mass.--(BUSINESS WIRE)--Sep. 13, 2017--
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the
appointment of Kristine Peterson to its Board of Directors. Ms. Peterson
will also serve as a member of the Compensation Committee and the
Nominating and Corporate Governance Committee of Enanta’s Board of
Directors. The appointment of Ms. Peterson increases the number of
Enanta Directors to seven.
“Kristine’s broad therapeutic marketing and commercialization experience
will be invaluable as we advance our development programs and when we
evaluate any new business opportunities for the company,” commented Jay
R. Luly, Ph.D. President and Chief Executive Officer. “I look forward to
her guidance during this period of growth for the company.”
Ms. Peterson has over 25 years of senior executive experience in
commercial and business leadership roles in the pharmaceutical and
biotechnology industry. From 2009 to 2016, Ms. Peterson served as Chief
Executive Officer of Valeritas, Inc., a commercial-stage medical
technology company where, under her leadership, the organization evolved
from a research stage company to a commercial enterprise. Previously she
held executive global marketing and commercial roles at Johnson &
Johnson from 2004 to 2009, most recently as Company Group Chair, Biotech
Sector, where she was responsible for commercial, R&D, and biologics
manufacturing for biotech, oncology, immunology and cell therapy. From
2003 to 2004, she served as Senior Vice President, Commercial Operations
for Biovail Corporation and President of Biovail Pharmaceuticals.
Earlier in her career, she spent 20 years at Bristol-Myers Squibb
Company in senior sales and marketing roles of increasing responsibility
in a broad range of therapeutic areas that included Cardiovascular,
Metabolic, Anti-infective, Virology, Neuroscience,
Immunology/Inflammation, Pulmonary, and Oncology.
Ms. Peterson currently serves on the Boards of Directors of Amarin
Corporation plc, ImmunoGen, Inc., Paratek Pharmaceuticals, Inc. and
pSivida Corp. She received a Master of Business Administration and a
Bachelor of Science from the University of Illinois at Urbana-Champaign.
Enanta Pharmaceuticals has used its robust,
chemistry-driven approach and drug discovery capabilities to become a
leader in the discovery of small molecule drugs for the treatment of
viral infections and liver diseases. Two protease inhibitors,
paritaprevir and glecaprevir, discovered and developed through Enanta’s
collaboration with AbbVie, have now been approved in jurisdictions
around the world as part of AbbVie’s direct-acting antiviral (DAA)
regimens for the treatment of hepatitis C virus (HCV) infection,
including the U.S. marketed regimens MAVYRET™ (glecaprevir/pibrentasvir)
and VIEKIRA PAK® (paritaprevir/ritonavir/ombitasvir/dasabuvir).
Royalties and milestone payments from the AbbVie collaboration are
helping to fund Enanta’s research and development efforts, which are
currently focused on the following disease targets: non-alcoholic
steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory
syncytial virus (RSV) and hepatitis B virus (HBV). Please visit www.enanta.com
for more information.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170913005121/en/
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.
MacDougall Biomedical Communications